TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:21
Dyne Therapeutics Inc. ( DYN ) https://www.dyne-tx.com
26.78USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
DYN
140.61%
SPY
32.74%
DYN
82.05%
SPY
92.93%
DYN
0.00%
SPY
224.41%
DYN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1793.66
1793.53
0.94
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-8.74
1.78
19.65
-37.36
0.00
-7.63
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-165.24
-127.02
0.00
Other Earnings and Cash Flow Stats:
Dyne Therapeutics Inc. ( DYN ) Net Income TTM ($MM) is -180.71
Dyne Therapeutics Inc. ( DYN ) Operating Income TTM ($MM) is -190.16
Dyne Therapeutics Inc. ( DYN ) Owners' Earnings Annual ($MM) is -183.50
Dyne Therapeutics Inc. ( DYN ) Current Price to Owners' Earnings ratio is -8.97
Dyne Therapeutics Inc. ( DYN ) EBITDA TTM ($MM) is -188.54
Dyne Therapeutics Inc. ( DYN ) EBITDA Margin is 0.00%
Capital Allocation:
Dyne Therapeutics Inc. ( DYN ) has paid 0.00 dividends per share and bought back -9.4924 million shares in the past 12 months
Dyne Therapeutics Inc. ( DYN ) has reduced its debt by 3.068 million USD in the last 12 months
Capital Structure:
Dyne Therapeutics Inc. ( DYN ) Interest-bearing Debt ($MM) as of last quarter is 27
Dyne Therapeutics Inc. ( DYN ) Annual Working Capital Investments ($MM) are -20
Dyne Therapeutics Inc. ( DYN ) Book Value ($MM) as of last quarter is 91
Dyne Therapeutics Inc. ( DYN ) Debt/Capital as of last quarter is 30%
Other Balance Sheet Stats:
Dyne Therapeutics Inc. ( DYN ) has 121 million in cash on hand as of last quarter
Dyne Therapeutics Inc. ( DYN ) has 51 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Dyne Therapeutics Inc. ( DYN ) has 61 common shares outstanding as of last quarter
Dyne Therapeutics Inc. ( DYN ) has 0 million USD of preferred stock value
Academic Scores:
Dyne Therapeutics Inc. ( DYN ) Altman Z-Score is 5.06 as of last quarter
Dyne Therapeutics Inc. ( DYN ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Dyne Therapeutics Inc. ( DYN ) largest shareholder is Geode Capital Management, LLC owning 857710 shares at 22.97 ($MM) value
Richard William Scalzo(an insider) Sold 2672 shares of Dyne Therapeutics Inc. ( DYN ) for the amount of $67548.16 on 2024-03-11
1.48% of Dyne Therapeutics Inc. ( DYN ) is held by insiders, and 109.47% is held by institutions
Dyne Therapeutics Inc. ( DYN ) went public on 2020-09-17
Other Dyne Therapeutics Inc. ( DYN ) financial metrics:
FCF:-171.31
Unlevered Free Cash Flow:-191.53
EPS:-3.92
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-263.81
Beta:0.00
Buffet's Owners Earnings:-183.50
Price to Owner's Earnings:-8.97
About Dyne Therapeutics Inc. ( DYN ) :
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.